No Data
No Data
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
CICC: Maintains cspc pharma (01093) 'Outperform' rating with a target price of HKD 8.4.
The stone medicine Baige trading plan has been announced. If this transaction is completed, the annual/1H24 revenue of Stone Medicine Innovation in 2023 will increase from 2.54/0.97 billion yuan to 4.79/1.89 billion yuan; net income attributable to shareholders will increase from 0.43/0.14 billion to 1.16/0.525 billion yuan.
cspc pharma (01093) canceled 49.59 million shares already repurchased.
cspc pharma (01093) announced that the company has canceled 49.59 million shares repurchased on October 15, 2024...
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
CSPC Pharma rose more than 6% in early trading. The group signed an exclusive licensing agreement with AstraZeneca.
CSPC Pharma (01093) rose 5.51% in early trading, now trading at 7.09 Hong Kong dollars, with a turnover of 0.585 billion Hong Kong dollars. CSPC Pharma has issued an announcement.
Intensive bullish news drives valuation repair, could CSPC Pharma (01093) turn bullish again with a new buying point?
The general upward trend may be coming to an end, and the subsequent on-site funds may pay more attention to the fundamentals and financial aspects of enterprises, with cspc pharma possibly remaining the target of fund chasing.